Trading at $231.56 vs DCF FV $154, P(above current)=2.6% — DCF strongly signals overvaluation. Old target $300 is aspirational and disconnected from model. Insulet makes strong devices but premium is extreme at current price. DCF divergence: cannot justify vs model without fresh catalyst.
Multiple red flags converging: DCF FV $132 vs $225 actual (P>cur ≈0%), voluntary device correction (18 SAEs), securities investigation, worst technicals in portfolio (RSI 33.2, tech -4). EVOLUTION 2 data keeps thesis alive but risk/reward deteriorating. Conv 6→5. Sell trigger: May 7 earnings disappoints on recall costs or guidance cut.
Was 8 when added Mar 5-9 on 10-K fundamentals. March 12 voluntary MDC for Omnipod 5 manufacturing defect is not a thesis-breaker but reduces conviction: (1) manufacturing QC is a core competency for AID systems, (2) stock hit 52-week low with elevated litigation risk, (3) 12% portfolio weight is too large for a conv-6 name. Trimming to ~5-6% weight. Retaining because T2D market, international Omnipod 5 ramp, and 41% upside to remain valid. Monitor May 28 earnings for management commentary on recall scope and cost.
Voluntary device correction for specific Omnipod 5 pod lots (internal tubing tear). 18 SAEs including hospitalizations/DKA — no deaths. $40M remediation cost excluded from adjusted guidance. 2026 guidance maintained. Stock at 52-week low. Trimming 8→7: execution risk and manufacturing quality control concern elevated near-term. Thesis intact (T2D expansion, closed-loop system), positive ATTD data, but the SAE disclosures and quality control remediation introduce uncertainty.
Raising conviction 7→8. Prior read confirmed but balance sheet improvement stronger than expected. 40% deleveraging in single year impressive. Growth reaccelerated to 30.7% (was 22% in FY24). Gross margin trajectory to 24%+ EBITDA margin credible at scale. International O5 ramp (44% growth) validates TAM expansion thesis. T2D clearance opens $3B+ addressable market. Pipeline de-risked: STRIVE complete for next-gen HCL, EVOLUTION 2 enrolled for FCL T2D. Key risks: tariff exemption removal would hit margins materially; GLP-1 competition narrative persists but pump demand remains strong. At $300/share ($21B mkt cap), valuation rich but growth quality supports it.
Fair Value Distribution — percentile bands
2.2% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
23.0%/yr
±5.3% · revenue growth to justify current price
FCF-Based Reverse DCF
30.3%/yr
±3.8% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
EVOLUTION 2 closed-loop type 2 data presenting at ATTD this week — first clinical proof of fully automated insulin delivery for T2D. Omnipod 5 growing 25%+ with international expansion runway (EU, Japan). RSI 39 near oversold with 30% upside to $310 target. Two catalyst events in the next 60 days.
Stock crashed 22% post-GLP-1 fear and hasn't recovered. If EVOLUTION 2 data disappoints, the T2D expansion thesis takes a major hit. Insulin pump market is competitive (Medtronic 780G, Tandem Mobi) and pricing pressure is real. Manufacturing scale-up for Omnipod 5 international is execution-dependent.
EVOLUTION 2 clinical failure, Omnipod 5 market share loss below 30%, GLP-1 proven to eliminate insulin pump need
Updated Mar 11
Insulet presented EVOLUTION 2 trial results showing 68% TIR for fully closed-loop automated insulin delivery in Type 2 adults at ATTD conference. Positive clinical validation of T2D market expansion t...
Insulet issued a voluntary correction for specific Omnipod 5 pod lots due to a small internal tubing tear causing insulin delivery failures. 18 serious adverse events including hospitalizations and DK...
Insulet presenting clinical results for Omnipod fully closed-loop (FCL) system in type 2 diabetes at ATTD 2026 in Barcelona today. This is new clinical data for their T2D FCL expansion — a major thesi...
FY2025 10-K confirms strong execution. Revenue +30.7% to $2.71B (const curr +29.5%). Gross margin 71.6% (+180bps). Adj EBITDA $645.5M (+41%). FCF $377.7M. Deleveraged 40% (debt $949M from $1.38B). Net...
Insulet delivered 30.7% revenue growth (.7B) with 180 bps gross margin expansion (71.6%) driven by manufacturing efficiency, ASP/mix, and volume leverage. Net debt down 40% (.4B→M) via .5M convertible...